Targeted multi-region lipidomics with proteomic and mitochondrial data reveals region- and stage-specific lipid alterations in Parkinson’s disease that converge on mitochondrial dysfunction
0:00Welcome to Base by Base, the paper cast that brings genomics to you, wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. Okay, let's jump right in. When we think about something like Parkinson's or Alzheimer's, our minds, will they go straight to proteins?
0:16Of course. You think of alpha to nuclean, you think of plaques and tangles, it feels like a protein problem. Exactly. But proteins don't just exist in a void. They're part of the brain. And the brain itself, by dry weight, is something like 60 to 70% fat, lipids.
0:31That's absolutely right. They are the building blocks. Every cell membrane, all the signaling. It's all built on a lipid foundation. It's like, if the bricks of your house are crumbling, You've got a problem no matter how good the plumbing is.
0:44So that's the big question for our deep dive today. What if we've been focusing so much on the protein aggregates in Parkinson's that we've missed the bigger picture? What happens when the very structure of the brain, that massive lifted environment starts to fail?
0:58Could Parkinson's be what you might call a lipidopathy as much as it is a proteinopathy? And the paper we're looking at gives an answer that is, well, it's not simple. No, it's incredibly specific. And this is where it gets so interesting.
1:12The study shows, these brain fats don't just, you know, decrease across the board. The changes depend entirely on where you are in the brain. And when you look, in terms of disease progression. It's not one big failure.
1:26It's more like a series of localized structural collapses. And to see that, to actually map it. That takes a phenomenal amount of work in precision. It really does. So today we really want to celebrate the work of Jenny Helquist, Christina E. Toomey and Wendy E.
1:42Heywood and their huge international team. They leveraged tissue bank samples in a way that just gives us this beautiful high resolution map of what's happening. They've really pushed our understanding forward.
1:53And this is so important because Parkinson's is the most common neurodegenerative movement disorder. We're talking over 6000000 people worldwide. And within aging population, that number is, unfortunately, only going up.
2:04For sure. And while everyone talks about genetics and proteins, the evidence for Lippins being a key player has been building for years. We've known for a while that alpha synocline aggregation is affected by lipids.
2:18The protein clumps themselves are actually full of fats. So what was the missing piece of the puzzle here? It was the map. The spatial temporal profile. We didn't know when or where these structural changes were happening as the disease progressed.
2:31You know, is it an early trigger or a late stage consequence? Okay, so before we get to their findings, let's quickly introduce the main characters. The 3 big lipid classes they studied. First up, sphingal lipids.
2:42Right. So Spingo lipids, things like Spingo Myelin and Sarah Mides. Think of these as the primary structural components. They're key for cell membranes for signaling. And Spingham Island specifically has been linked to how alpha cynically and spreads, right?
2:55That's right, from cell to cell. Okay, next class. Glycos fingalipids. This includes things like glucosilceramide or hexer. And this one is a huge deal in Parkinson's research. A problem in the pathway that breaks down these lipids, is linked to the single most common genetic cause of PD.
3:13The GBA one mutation. GBA one mutation, exactly. So any changes here could be a really important clue. So that's two. 3rd and final group? That would be the phosphilipids. This includes things like LysoTC and a special group called Plasmologens.
3:27And they're also part of the membrane structure. They are, but some, like the PE plasmalogens, also act as really powerful antioxidants in the brain. They help clean up damaging reactive oxygen species.
3:39That sets the stage perfectly. So how did the team actually measure all of this with such precision? Well, this is where the scale of this study is so impressive. They took 225 postmortem biopsies from 8 different brain regions.
3:52Eight regions. So we're talking the Kade, Pudemen, frontal cortex. The cerebellum, yes. A really comprehensive anatomical spread. And they didn't just group them into healthy and PD. No, they staged them.
4:03Exactly. They had controls, mid-stage PD, and late stage PD based on something called break staging. Could you just quickly remind us what break stages mean? Of course. It's basically a roadmap for how Parkinson's pathology spreads.
4:17It starts low in the brain stem, and stage 3 to 4 means it's hit those key subcortical areas like the substantiate Negra, that control movement. In stage 5 to six. That's when it's spread out to the cortex, the outer brain layer, which is usually linked to later cognitive symptoms.
4:31So they weren't just comparing a PD brain to a healthy brain. They were comparing, say, an early stage Putimen to a late stage frontal cortex. Precisely. The resolution is just orders of magnitude higher.
4:42And what technology did they use to measure the 146 different lipids? They use targeted liquid chromatography, mass spectrometry or LCMSMS. It's the gold standard for this kind of work. It lets you identify and quantify very specific molecules with high accuracy.
4:58But I imagine one huge challenge is that our brains change just from getting older. How did they account for that? That was a really, really rigorous part of the study. First, they analyzed all the control samples to map out what normal brain aging looks like, libid wise.
5:12So they found a baseline for healthy aging. Yes. For example, they saw that an hexosylsromide tends to go up with age pretty much everywhere. So they took that pattern and used it to age adjust all the PD data.
5:25So every change they report is purely disease related, not just an effective aging. That's the goal. It's how you get to a true pathological signal. And they didn't just stop there, did they? They added another layer.
5:37No, they didn't. And this is the multi-omic part. They correlated all this new lipid data with existing proteomics data from the very same tissue samples. Which means they could directly link a change in structure, say, a certain fat disappearing to a change in function, like a specific energy pathway failing.
5:57Exactly. It connects the dots in a really powerful way. Okay, that methodology is just so thorough. Let's get to what they found. What does a healthy brain look like? lipit wise? Well, the 1st thing is that it's not uniform at all.
6:08The lipid makeup of the cerebellum is just different from the cottage. That makes sense. But what's really interesting is that ceramides, those critical structural lipids, were the most consistent across all regions.
6:19Only about 15% variation. Which suggests their levels are really tightly controlled. Very tightly. In contrast, something like LysopE varied by over 50%, depending on where you looked. Okay, so ceramides are stable and vital in a healthy brain.
6:34So what happens when Parkinson's hits? Is there one single change that happens everywhere? There is a kind of global signature, yes. Overall, PD brains had higher levels of certain gagliocides, GM one, GM 2, GM 3, and also Morse Fingum Island.
6:51But the real story, the very specific one, was in the ceremites. And this is where it gets technical, but so important. It all comes down to the length of their carbon tails, the chain length. Because that link determines the fats function in the membrane, right?
7:04It absolutely does. And what they found was that the shorter ones, the C 16 and C 18 ceremites were elevated pretty much everywhere in PD brains. They were a key marker separating PD from controls. Wait, so the brain is making more of these shorter maybe less staple fats.
7:18It seems to be part of the global response, yes. But here's the flip side. The really stable ones. The very long chain ceremites, C20 and longer. What about them? They were going down. They were being depleted, but specifically in a key motor region, the pudimin.
7:36Wow. So it's not just ceremites change. The brain is breaking down its most stable structural fats in the motor control center while building up shorter ones elsewhere. You've got it. And that discovery allowed them to group all the brain regions into 2 distinct clusters based on their molecular signature.
7:53Okay, tell us about these clusters. First, you have the cortical cluster, then frontal cortex, areas affected later in the disease. This cluster showed increases in glycosfingal lipids, like gangliocides and hexer.
8:05Which fits the idea of the disease spreading outwards later on. It does. And then you have the subcortical cluster. This is the pudamen and caudate. The areas hit early on that control movement. And they had a totally different signature.
8:16A completely different chemical fingerprint. They had decreases in those glycosfinger lipids, but increases in certain phosphol lipids. The putamin just showed the most profound changes overall. Let's zoom in on the Putamen then.
8:29How early did these changes appear? Very early. In midstage PD. So break stage 3 to 4. That's when you see this widespread depletion of stink libids, that critical drop in the very long chain ceremines, and also in the antioxid implies mealagin PE.
8:44It's an early foundational collapse. The detail here is just stunning. Let's pivot now from the what to the Y. What does the structural failure mean for the cell's ability to, you know, survive and make energy?
8:56This is where connecting to the proteomics data was so crucial. They found that the lipids that were changing in the putament, the plasma Belgian PE, the very long teen ceramites were significantly correlated with the decrease in mitochondrial complex hike contivity.
9:09So a structural failure is directly linked to an energy failure. In the exact same place. And this isn't a vague correlation. It's very strong statistical link. It suggests these 2 problems, lipid dysregulation, and mitochondrial failure are feeding each other.
9:23It sounds like a pathological handshake happening right where the disease is taking hold. It does. And this brings us back to that seramide paradox. Why are the shorter C 16 and C 18 ceremonies going up everywhere?
9:36Right. The hypothesis is that they're being made through the do novosynthesis pathway. The cell knows it's losing ceremites. Maybe because the cleanup pathway is broken like in GBA one mutations. So it's desperately trying to make new ones from scratch.
9:51And is it possible that this attempt to fix the problem is actually making things worse? That's precisely the idea. The C 18 ceramide in particular is thought to trigger an alternative pathway for clearing out damaged mitochondria, a process called mitophagy.
10:05And if that alternative pathway is defective, then you end up with a buildup of damaged energy deficient mitochondria, creating this vicious cycle of failure right there in the pudiment. So a protective mechanism gone wrong.
10:17But did they see any signs of what might be a successful protective mechanism? Yes, absolutely. It looks like the brain is trying to adapt. For instance, the increase in ganglaside GM one in the cortical areas, later in the...
10:31Well, GM one has known neur restorative properties. So it's the brain trying to repair itself. Or the late stage increase in the antioxidant plasmalogen PE in the Putamen. That could be a direct response to fight the oxidative stress from the feeling mitochondria.
10:45What about LysopC? You mentioned that one earlier. It went up and was highest in the cerebellum, a region that's mostly spared by PD. Lyso PC is a bit of a puzzle. It's high levels in a healthy area like the cerebellum might suggest it's protective.
11:00Maybe shielding that region from Alpha's nucleum. But it's not that simple. The researchers point out that other studies are conflicting. Some even suggest it could promote aggregation, so we really need to figure out if it's a friend or foe.
11:12So at the end of the day, what does this all mean for finding a treatment? We can't just develop a drug that's, say, boosts all ceremonides everywhere. No, you absolutely can't. This work really argues that we have to move beyond thinking of the PD brain is one thing.
11:27Therapeutics will likely need to be region specific and stage specific. So for early stage PD, you might need a drug that targets the Putimin specifically. A drug that can restore those very long chain ceramides or boost mitochondrial complex eye function right there in that subcortical cluster before the damage spreads.
11:45I think that's the ultimate take home message. Parkinson's isn't a single event. It's a regionally distinct process, and we can see it reflected in the very bricks and mortar of the brain. The central insight is that balance.
11:57The specific balance between short and long chain ceramides and its direct link to mitochondrial failure in the pudimin. That seems to be a critical early convergence point that we can now track. Which leaves us with a really provocative thought.
12:11Given this incredibly detailed link between anatomy, disease stage, and molecular profile, what does this mean for developing truly personalized therapies that can target the signature of Parkinson's disease exactly where and when it begins?
12:24This episode was based on an open access article under the CCBY4.0 license. You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a five-star rating.
12:37If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created especially for this episode and inspired by the article you've just heard about.
12:46Thanks for listening and join us next time as we explore more science, base by base.
